CRNX

CrineticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

Successful late-stage readouts and favorable regulatory interactions drive rapid adoption in target endocrine indications, justifying significant upside to the anchor price.

Posture

Defensive

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +5.4.

What can break

Commercial uptake slower than modeled

Momentum

100

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $48.00 · Bull $85.00 · Bear $22.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-01-03 • Model: RankAlpha Sentiment AI

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net —

Target $82.50

Why

Momentum100 · Δ7d +5.4

Value41 · Δ7d -0.1

Sentiment7 · Δ7d -1.5

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Momentum · See technicals

Momentum

100

26% active weight

Current posture

7d trendFlat

Δ7d

+5.4

Δ21d

+82.1

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

0.0

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-1.5

Δ21d

-76.3

Why this grade

Composite grade D. Momentum 99.8 / Value 41.1 / Sentiment 6.7

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$8.88B

Beta

0.20

Shares Out

105.84M

P/E (TTM) · Derived

-17.0

P/S (TTM)

2978.43

P/FCF (TTM) · Derived

-19.41

Rev YoY

+2873.4%

EPS YoY

+18.2%

Gross Margin

+70.1%

Op Margin

-31130.2%

Net Debt

-$979.35M

Current Ratio

18.60

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology